3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
43
Leukemia, Myeloid, Acute
25
Recurrence
21
Lymphoma, Large B-Cell, Diffuse
12
Sarcoma
8
Neoplasms, Plasma Cell
5
Neoplasm Metastasis
5
Lymphoma
5
Glioblastoma
5
Ovarian Neoplasms
4
Neurofibrosarcoma
4
Neoplasms
4
Melanoma
4
Lymphoma, Non-Hodgkin
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Liposarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Waldenstrom Macroglobulinemia
2
Thymoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdoid Tumor
2
Interventions
Pemetrexed
10
Cisplatin
9
Carboplatin
9
pembrolizumab
8
Nivolumab
8
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
ribociclib
4
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Cyclophosphamide
4
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
Anastrozole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Site
×
selinexor
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled